October 2nd - 4th | Boston, MA
Applied BioMath Presence:
Tuesday, October 3rd | 2:15pm ET
Title: Using mathematical modeling to find a balance between affinity and avidity for an optimal therapeutic window
- For cis-binding bispecific molecules, weaker single-target binding affinity with stronger avidity is used as a strategy to reduce the chances of the drug binding to off-target cells, thereby increasing the therapeutic window.
- However, the development of a molecule is more complicated once multiple targets are involved. Binding affinities to multiple targets can be optimized; in addition, the expression levels of multiple targets need to be considered when translating from preclinical to clinical.
- Mechanistic PKPD models that capture the biophysics of binding and avidity are a powerful tool to guide compound selection and clinical translation. We will demonstrate how to develop a mechanistic PKPD model for bispecifics and how to use the model to predict an optimal therapeutic window.
Presenter: Fei Hua, PhD, Vice President of Modeling and Simulation Services
Title: Predicting on-target, off-tumor toxicity of Solitomab, an EpCAM/CD3 BiTE
Presenter: John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
This is a Hanson Wade conference.